Disease · MONDO_0001627
dementia
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. dementia. Diseases, record MONDO_0001627. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0001627
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Highest stage of its drugs
- Approval, for 20 of its 96 drugs, from ATC, DailyMed, EMA Human Drugs, FDA, PMDA and TTD
- Open Targets
Drugs96
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| DONEPEZIL | CHEMBL502 | Small molecule | Approval | ATC and PMDA | 8 | 6 | 6 | Drugs and targets |
| MEMANTINE | CHEMBL807 | Small molecule | Approval | ATC | 5 | 4 | 4 | Drugs and targets |
| RIVASTIGMINE | CHEMBL636 | Small molecule | Approval | ATC, DailyMed, EMA Human Drugs and PMDA | 16 | 3 | 3 | Drugs and targets |
| DONEPEZIL HYDROCHLORIDE | CHEMBL1678 | Small molecule | Approval | DailyMed and PMDA | 54 | 2 | 2 | Drugs and targets |
| GALANTAMINE | CHEMBL659 | Small molecule | Approval | ATC | 3 | 2 | 2 | Drugs and targets |
| GALANTAMINE HYDROBROMIDE | CHEMBL1555 | Small molecule | Approval | DailyMed and PMDA | 4 | 1 | 1 | Drugs and targets |
| MEMANTINE HYDROCHLORIDE | CHEMBL1699 | Small molecule | Approval | DailyMed and PMDA | 7 | 0 | 0 | Drugs and targets |
| IOFLUPANE I 123 | CHEMBL3989517 | Small molecule | Approval | EMA Human Drugs and PMDA | 3 | 0 | 0 | Drugs and targets |
| DONANEMAB | CHEMBL4297245 | Antibody | Approval | ATC and PMDA | 2 | 0 | 0 | Drugs and targets |
| LECANEMAB | CHEMBL3833321 | Antibody | Approval | ATC and PMDA | 2 | 0 | 0 | Drugs and targets |
1 to 10 of 96
See all 96 drugsTargets141
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ACHE | Acetylcholinesterase | 8 | Acetylcholinesterase inhibitor; Cholinesterases; ACHE & BCHE inhibitor | Approval | https://conductscience.org/library/genes/43 | Drugs and targets |
| DRD2 | D(2) dopamine receptor | 7 | D2-like dopamine receptor agonist; D2-like dopamine receptor antagonist; Dopamine D2 receptor antagonist; Dopamine D2 receptor partial agonist; Dopamine receptors; D2 & D3 antagonist | Phase 3 | https://conductscience.org/library/genes/1813 | Drugs and targets |
| HTR2A | 5-hydroxytryptamine receptor 2A | 6 | Serotonin (5-HT) receptor antagonist; Serotonin 2a (5-HT2a) receptor antagonist | Phase 3 | https://conductscience.org/library/genes/3356 | Drugs and targets |
| AGTR1 | Type-1 angiotensin II receptor | 5 | Type-1 angiotensin II receptor antagonist | Phase 2 | https://conductscience.org/library/genes/185 | Drugs and targets |
| HTR2C | 5-hydroxytryptamine receptor 2C | 5 | Serotonin (5-HT) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist | Phase 3 | https://conductscience.org/library/genes/3358 | Drugs and targets |
| APP | Amyloid-beta precursor protein | 4 | Amyloid-beta A4 protein binding agent; Amyloid-beta A4 protein disrupting agent; Amyloid-beta A4 protein inhibitor | Approval | https://conductscience.org/library/genes/351 | Drugs and targets |
| BCHE | Cholinesterases; ACHE & BCHE | 3 | Cholinesterases; ACHE & BCHE inhibitor | Approval | https://conductscience.org/library/genes/590 | Drugs and targets |
| DRD3 | D2-like dopamine receptor | 3 | D2-like dopamine receptor agonist; D2-like dopamine receptor antagonist; Dopamine receptors; D2 & D3 antagonist | Phase 1/2 | https://conductscience.org/library/genes/1814 | Drugs and targets |
| GABRA1 | GABA-A receptor; anion channel | 3 | GABA-A receptor; anion channel positive allosteric modulator | Unknown | https://conductscience.org/library/genes/2554 | Drugs and targets |
| GABRA2 | GABA-A receptor; anion channel | 3 | GABA-A receptor; anion channel positive allosteric modulator | Unknown | https://conductscience.org/library/genes/2555 | Drugs and targets |
1 to 10 of 141
See all 141 targetsTrials73
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01900665 | Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo | Phase 3 | 2,129 | 2018-03-14 | Alzheimer's Disease | SOLANEZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02446132 | Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type | Phase 3 | 1,197 | 2025-10-15 | Agitation in Patients With Dementia of the Alzheimer's Type | DEUDEXTROMETHORPHAN, QUINIDINE SULFATE | Its record names the disease | ClinicalTrials.gov |
| NCT02669433 | Study Evaluating Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: The HEADWAY-DLB Study | Phase 2 | 484 | 2019-04-26 | Dementia With Lewy Bodies | INTEPIRDINE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02615002 | Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION) | Phase 2 | 371 | 2024-07-05 | Alzheimer's Disease | PIROMELATINE | Its record names the disease | ClinicalTrials.gov |
| NCT03305809 | A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB) | Phase 2 | 344 | 2021-07-23 | Lewy Body Dementia | MEVIDALEN | Its record names the disease | ClinicalTrials.gov |
| NCT03467152 | Study To Evaluate the Efficacy, Safety and Tolerability of E2027 (Hereinafter Referred to as Irsenontrine) in Participants With Dementia With Lewy Bodies | Phase 2 | 326 | 2022-08-01 | Dementia With Lewy Bodies | IRSENONTRINE | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT02660983 | A Study of Donepezil Hydrochloride in Patients With Dementia Associated With Cerebrovascular Disease | Phase 4 | 302 | 2019-10-04 | Dementia Associated With Cerebrovascular Disease | DONEPEZIL HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT02727699 | A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu) | Phase 2 | 185 | 2021-05-06 | Dementia, Alzheimer Type | EMESTEDASTAT | Its record names the disease | ClinicalTrials.gov |
| NCT05271552 | Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II) | Phase 3 | 151 | 2025-12-31 | Agitation, Dementia | DEXMEDETOMIDINE | Its record names the disease | ClinicalTrials.gov |
| NCT04117178 | Monitoring Anti-Dementia Drugs by Serum Levels | Phase 4 | 132 | 2025-02-10 | Dementia, Dementia With Lewy Bodies, Dementia in Parkinsons Disease, Dementia Alzheimers, Alzheimer Disease | DONEPEZIL, MEMANTINE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 73
See all 73 trialsComparisons in its trials15
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Irsenontrine 50 mg vs Placebo: deaths from any cause | 0 of 99 | 1 of 97 | 196 | NCT03467152 | Trial comparisons |
| Irsenontrine 50 mg vs Placebo: Number of Participants With Orthostatic Tachycardia | 0 of 99 | 1 of 97 | 196 | NCT03467152 | Trial comparisons |
| Irsenontrine 50 mg vs Placebo: serious adverse events | 7 of 99 | 9 of 97 | 196 | NCT03467152 | Trial comparisons |
| Xanamem™ vs Placebo: deaths from any cause | 0 of 91 | 0 of 94 | 185 | NCT02727699 | Trial comparisons |
| Xanamem™ vs Placebo: serious adverse events | 4 of 91 | 4 of 94 | 185 | NCT02727699 | Trial comparisons |
| Intervention Arm vs Standard of Care: deaths from any cause | 2 of 67 | 2 of 65 | 132 | NCT04117178 | Trial comparisons |
| Intervention Arm vs Standard of Care: serious adverse events | 7 of 67 | 6 of 65 | 132 | NCT04117178 | Trial comparisons |
| Active (AMX0035) vs Placebo: deaths from any cause | 0 of 51 | 0 of 44 | 95 | NCT03533257 | Trial comparisons |
| Active (AMX0035) vs Placebo: Number of Participants With Treatment-Emergent Adverse Event (TEAEs) | 34 of 51 | 26 of 44 | 95 | NCT03533257 | Trial comparisons |
| Active (AMX0035) vs Placebo: serious adverse events | 3 of 51 | 1 of 44 | 95 | NCT03533257 | Trial comparisons |
1 to 10 of 15
See all 15 comparisons in its trialsPapers from its trials44
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0001627
GET https://conductscience.org/api/diseases/v1/MONDO_0001627/drugs?page=2